Algen Biotechnologies, AstraZeneca form AI drug discovery partnership

Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds

A Mayo Clinic has developed an artificial intelligence model that can help specialists detect pancreatic cancer on routine abdominal CT scans up to three years before clinical diagnosis. It identifies subtle signs of disease before tumors are visible, when curative treatment may still be possible.

May 01, 2026

Vol.52 No.17

Drugs & Targets

Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule

Unfold AI, an AI prostate cancer mapping and clinical decision support platform, is now included in Medicare’s Physician Fee Schedules across the West Coast and Mountain West regions. The regional expansion of Medicare payment for the tool gives urologists and care teams clearer reimbursement pathways in physician office settings, an area that has historically lagged behind hospital outpatient settings for emerging technologies.

May 01, 2026

Vol.52 No.17

In Brief

UT Austin announces first tech-native academic medical center in the U.S.

The University of Texas at Austin is building an integrated academic medical center from the ground up, where care, research, and education operate as one system organized around the patient. This model connects prevention, diagnosis, treatment, and long-term health into a continuous experience, particularly for those with complex and serious conditions.

April 24, 2026

Vol.52 No.16

In Brief

Lisa Eli named chief scientific officer at Zephyr AI

Lisa Eli has been appointed chief scientific officer at Zephyr AI Inc.

April 24, 2026

Vol.52 No.16

Clinical Roundup

Cancer AI Alliance announces first wave of pilot projects

Cancer AI Alliance announced its first wave of eight pilot projects across a federated learning platform. These projects represent the first wave of the organization’s efforts and aim to demonstrate that it is possible to analyze vast amounts of data while keeping patient privacy secure at the local level.

April 10, 2026

Vol.52 No.14

Clinical Roundup

UVA scientists use AI to improve success rate for new drugs, reduce costs

University of Virginia School of Medicine scientists have developed an approach to drug development and discovery that could dramatically accelerate the creation of new medicines.

April 03, 2026

Vol.52 No.13

Algen Biotechnologies, AstraZeneca form AI drug discovery partnership

YOU MAY BE INTERESTED IN

Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds

Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule

UT Austin announces first tech-native academic medical center in the U.S.

Lisa Eli named chief scientific officer at Zephyr AI

Cancer AI Alliance announces first wave of pilot projects

UVA scientists use AI to improve success rate for new drugs, reduce costs

Renew today!

Subscriber content

Never miss an issue!

Login